Invitation to the special and extraordinary shareholders' meetings
Mechelen, Belgium; 20 September 2019, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) invites its shareholders to a special and extraordinary shareholders' meeting.
On 14 July 2019, Galapagos NV (the "Company" or "Galapagos") announced that it entered into a collaboration with Gilead Sciences, Inc., Gilead Biopharmaceutics Ireland UC, and Gilead Therapeutics A1 Unlimited Company. In view hereof, Galapagos has the honor to invite its shareholders, warrant holders, directors, and statutory auditor to its special and extraordinary shareholders' meetings that will be held on Tuesday 22 October 2019 at 2:00 p.m. (CEST) at the Company's registered office.
The items on the agenda of the special and extraordinary general meetings of shareholders include, amongst other things, the appointment of Mr. Daniel O'Day and Dr. Linda Higgins as directors of the Company, the approval of the issuance of two warrants for the benefit of Gilead Therapeutics A1 Unlimited Company, and the renewal of the Company's authorized capital by up to 20% of the share capital.
In order to be admitted to the shareholders' meetings, the holders of securities issued by the Company must comply with article 536 of the Belgian Companies Code of 7 May 1999 and article 29 of the Company's articles of association, and fulfill the formalities described in the convening notice. The convening notice and other documents pertaining to the shareholders' meetings, including the biographies of Mr. O’Day and Dr. Higgins, can be consulted on our website (www.glpg.com ).
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.
Contact
| Investors: | Media: |
| Elizabeth Goodwin | Carmen Vroonen |
| VP IR | Senior Director Communications |
| +1 781 460 1784 | +32 473 824 874 |
| Sofie Van Gijsel | Evelyn Fox |
| Director IR | Director Communications |
| +32 485 19 14 15 | +31 6 53 591 999 |
| ir@glpg.com | communications@glpg.com |
Forward-looking statements
This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.
Disclaimer
The contents of our website, including the special reports prepared by the board of directors and the statutory auditor at the occasion of the shareholders' meetings of 22 October 2019, and any other website that may be accessed from our website, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Attachments
About GlobeNewswire
GlobeNewswireGlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Signify to acquire Cooper Lighting Solutions to strengthen its position in the attractive North American lighting market15.10.2019 22:24:00 CEST | Press release
Press release October 15, 2019 Signify to acquire Cooper Lighting Solutions to strengthen its position in the attractive North American lighting market Signify to acquire Cooper Lighting Solutions from Eaton for USD 1.4 billion in cash Clear strategic fit: Strengthening Signify’s market positions in North America, with increased innovation power and more competitive offerings; Improving the business mix with Professional revenues increasing from 42% to 53% of total sales1 Respective agent networks and front office functions will continue to operate independently Substantial value creation opportunity: cost synergy potential with savings of more than USD 60 million per year, to be largely achieved in the first three years Compelling financial metrics: mid-teens EPS accretion in year 1; transaction ROIC to exceed WACC after year 1 Transaction fully funded with debt; committed bridge financing in place Upon closing of the acquisition: Capital allocation priority is to deleverage. Strong f
Nexstim Plc: Invitation to the Extraordinary General Meeting of Shareholders15.10.2019 17:50:00 CEST | Press release
Nexstim Plc: Invitation to the Extraordinary General Meeting of Shareholders Company announcement, inside information, Helsinki 15 October 2019 at 6.50 PM (EEST) Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") – the company developing and marketing a unique brain stimulation technology for personalized treatment of major depressive disorder (MDD), invites the shareholders to attend the Extraordinary General Meeting of Shareholders of the Company on 11 November 2019 commencing at 10.00 (EEST) at the auditorium of Hotel Haven, Unioninkatu 17 Helsinki, Finland. The reception of persons who have registered for the meeting will commence at 9.30. A. Matters on the agenda of the Extraordinary General Meeting of Shareholders At the Extraordinary General Meeting of Shareholders, the following matters will be considered: 1 OPENING OF THE MEETING 2 CALLING THE MEETING TO ORDER 3 ELECTION OF PERSONS TO SCRUTINIZE THE MINUTES AND TO SUPERVISE THE COUNTING OF VOTES 4 RECORDING THE LEGALI
Nexstim Abp: Kallelse till extra bolagsstämma15.10.2019 17:50:00 CEST | Pressemelding
Nexstim Abp: Kallelse till extra bolagsstämma Pressmeddelande, insiderinformation, Helsingfors 15 oktober 2019, kl. 18.50 (EEST) Nexstim Abp (NXTMH:HEX, NXTMS:STO) (”Nexstim” eller ”Bolaget”), ett företag som utvecklar och marknadsför en unik hjärnstimuleringsteknologi för personlig behandling av egentlig depression (eng. Major Depression Disorder), kallar härmed aktieägarna till extra bolagsstämma 11 november 2019, kl. 10.00 (EEST) i auditoriet på Hotel Haven, Unionsgatan 17 i Helsingfors, Finland. Mottagandet av personer som har registrerat sig för bolagsstämman inleds kl. 9.30. A. Ärenden på extrastämmans dagordning Vid extrastämman ska följande ärenden behandlas: 1 STÄMMANS ÖPPNANDE 2 STÄMMANS KONSTITUERING 3 VAL AV PROTOKOLLJUSTERARE OCH RÖSTRÄKNARE 4 FASTSTÄLLELSE AV ATT STÄMMAN BLIVIT BEHÖRIGEN SAMMANKALLAD 5 FASTSTÄLLANDE AV NÄRVAROLISTA OCH RÖSTLÄNGD 6 STYRELSEKOMMITTÉER OCH INRÄTTANDET AV VALBEREDNINGEN FÖR AKTIEÄGARNA Bolaget har haft två styrelsekommittéer: styrelsens revis
DNO ASA: Mandatory Notification of Trade15.10.2019 17:43:00 CEST | Press release
Oslo, 15 October 2019 - DNO ASA, the Norwegian oil and gas operator, has today purchased 1,100,000 own shares at an average price of NOK 12.6653 per share. Following this transaction, DNO holds 75,500,000 own shares. -- For further information, please contact: Media: media@dno.no Investors: investor.relations@dno.no -- DNO ASA is a Norwegian oil and gas operator focused on the Middle East and the North Sea. Founded in 1971 and listed on the Oslo Stock Exchange, the Company holds stakes in onshore and offshore licenses at various stages of exploration, development and production in the Kurdistan region of Iraq, Norway, the United Kingdom, Netherlands, Ireland and Yemen. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Ress Life Investments A/S publishes Net Asset Value (NAV) per share.15.10.2019 17:20:00 CEST | Press release
Ress Life Investments Holbergsgade 14, 2 tv DK-1057 Copenhagen K Denmark CVR nr. 33593163 www.resslifeinvestments.com To: Nasdaq Copenhagen Date: 15 October 2019 Corporate Announcement 34/2019 Ress Life Investments A/S publishes Net Asset Value (NAV) per share. Ress Life Investments A/S publishes the Net Asset Value (NAV) per share as of 30 September 2019. NAV per share in USD: 1918.35 NAV per share in EUR: 1761.73 The performance during September 2019 was 0.97% in USD. The performance during the month was positively affected by one policy paying out and mark-to-market adjustments. The year-to-date net performance as of 30 September 2019 is 5.76% in USD. Assets under management (AUM) as of 30 September 2019 was 155.1 million US dollars. Questions related to this announcement can be made to the company's AIF-manager, Resscapital AB. Contact person: Gustaf Hagerud gustaf.hagerud@resscapital.com Tel + 46 8 545 282 27 Note: The terms for subscription of shares, minimum subscription amount
GOGL – Repurchase of shares15.10.2019 16:44:00 CEST | Press release
Golden Ocean Group Limited (“Golden Ocean” or the “Company”) announces that the Company has, on October 15, 2019 purchased 50,000 of the Company's own common stocks. The shares have been bought on the Oslo Stock Exchange at an average price of NOK 53.96 per share. After this transaction Golden Ocean holds a total of 1,250,000 own shares. The transaction is part of the share buyback program announced on December 20, 2018. Hamilton, Bermuda October 15, 2019 This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.